ONO-4538 Phase II Rollover Study (ONO-4538-98)

Sex: All

Ages: 16 Years – N/A

Healthy volunteers: No

Phase: PHASE2

Enrollment: 70

Sponsor: Ono Pharmaceutical Co., Ltd.

Summary

This study is intended to confirm the long-term safety of ONO-4538 in pan-tumor participants being treated with ONO-4538 monotherapy or in Combination with Other Therapies in clinical trials.

Eligibility Criteria

Inclusion Criteria: 1. Participant who is being treated with ONO-4538 as monotherapy or in Combination with Other Therapies in clinical trials 2. Participant who is eligible for ONO-4538 monotherapy or in combination with other therapies as per the clinical trials, and/or investigator-assessed clinical benefit Exclusion Criteria: 1. Participant judged to be incapable of providing consent for reasons such as concurrent dementia 2. Participant judged by the investigator to be inappropriate as participants of this study

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT04566380). StuddyBuddy aggregates publicly available trial information.